

Haematologica  
HAEMATOL/2016/147728  
Version 4

Guideline for the diagnosis, treatment and response criteria for Bing  
Neel syndrome

Monique C. Minnema, Eva Kimby, Shirley D'Sa, Luc-Matthieu Fornecker, Stéphanie Poulain, Tom J. Snijders, Efstathios Kastritis, Stéphane Kremer, Aikaterini Fitsiori, Laurence Simon, Frédéric Davi, Michael Lunn, Jorge J. Castillo, Christopher J. Patterson, Magali Le Garff-Tavernier, Myrto Costopoulos, Véronique Leblond, Marie-José Kersten, Meletios A. Dimopoulos, and Steven P. Treon

Disclosures: Disclosures MCM received honoraria from Amgen, Celgene, Jansen, Takeda and BMS. EK was speaker for Janssen, Onyx , Takeda, SD received honoraria from Janssen. MPL was on Advisory Board of CSL Behring, Baxter Pharmaceuticals. Research funding: CSL Behring. Speaker: CSL Behring, Grifols, Kedrion. Honoraria: CSL Behring, Grifols. EK received honoraria from Amgen, Janssen and Takeda. JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. VL research funding and consulting for Roche, Janssen Pharmaceuticals, Gilead, BMS, GSK, MundiPharma. MJK received research funding honoraria from Celgene and Jansen. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. LMF, SP, TSJ , SK, AF, LM, FD, ML, CJP, MGF, and MC have no disclosures.

Contributions: MCM and SPT wrote the manuscript, all authors contributed, reviewed and discussed the data during 3 separate conference calls and reviewed and approved the final version